Keros Therapeutics, Inc. (KROS) — Stock Score Summary

Keros Therapeutics, Inc. (KROS) has a MoatMap StockRank of 15/100 based on Quality (43/100), Value (43/100), and Momentum (13/100) factor scores. The current signal is STRONG SELL. Keros Therapeutics is a clinical-stage biotech company. Despite a moderate quality score of 43, it lacks the commercialized products, pricing power, and predictable free cash flows required by our investment philosophy.

Keros Therapeutics, Inc. is a U.S. clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for musculoskeletal and rare blood disorders. The company's innovative approach targets the transforming growth factor-beta (TGF-ß) superfamily, aiming to create first-in-class treatments for areas with significant unmet medical needs. Its competitive strategy is centered on a deep understanding of disease biology and a proprietary drug discovery platform to address specific, high-value indications.

Key Financial Metrics

Price$10.50
Market Cap$225M
P/E (Forward)-1.93
Price/Book0.74
Return on Equity-16.8%
Return on Invested Capital21.3%
Debt/Equity5.71
Gross Margin-184.9%
Operating Margin-7051.0%
Revenue Growth-99.8%
Free Cash Flow$-38M

Keros Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Keros Therapeutics, Inc.’s (KROS) StockRank?
MoatMap’s StockRank for Keros Therapeutics, Inc. (KROS) is 15/100, with a Strong Sell signal. It is a composite of Quality (43), Value (43), and Momentum (13) factor ranks across MoatMap’s 19,000+ stock universe.
Does Keros Therapeutics, Inc. have an economic moat?
Keros Therapeutics, Inc. (KROS) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Keros Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Keros Therapeutics, Inc. (KROS) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Keros Therapeutics, Inc. in?
Keros Therapeutics, Inc. (KROS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksKROS deep dive reportAI ChampionsHow we score stocksSense-check another stock